SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Encysive Pharmaceuticals (ENCY) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (193)6/25/2007 6:57:02 PM
From: Robohogs  Respond to of 205
 
LOL

Jon



To: rkrw who wrote (193)7/22/2007 4:44:35 PM
From: tuck  Respond to of 205
 
I suppose you noticed that indeed, they are exploring "strategic alternatives" with an I-bank, sending the shares up a bit. Good thing, because having looked a little at the dispute resolution process, it would appear to be a low odds, long process, as summed up here:

eyeonfda.com

When I started this thread, I noted that Revotar had licensed an ENCY compound in P2 for RA. It appears dead in the water. In almost two years, nada.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News